Format

Send to

Choose Destination
Lancet. 2002 Sep 21;360(9337):923-4.

Rituximab for idiopathic membranous nephropathy.

Author information

1
Ospedali Riuniti Di Bergam, Unit of Nephrology and Dialysis, Aldo and Cele Daccò Clinical Research Centre for Diseases, Mario Negri Institute for Parmacological Research, Via Gavazzeni 1124125, Bergamo, Italy. gremuzzi@marionegri.it

Erratum in

  • Lancet 2002 Dec 21-28;360(9350):2090.

Abstract

Treatments for idiopathic membranous nephropathy, a common cause of nephrotic syndrome, can be very toxic. In view of the pathogenic potential of B cells in this disease, we studied the effects of four weekly infusions of rituximab (375 mg/m(2)-- the monoclonal antibody to B-cell antigen CD20--in eight patients who had idiopathic membranous nephropathy with persistent nephrotic syndrome. At weeks 4 and 20, urinary protein decreased from mean (SE) 8.6 g/24 h (1.4) to 3.8 (0.8) and 3.7 (0.9), respectively (p<0.0001). At week 20, albuminuria and albumin fractional clearance decreased by 70% and 65%, and serum albumin increased by 31%. CD20 B lymphocytes fell below normal ranges up to study end. The short-term risk-benefit profile of rituximab seems more favourable to that of any other immunosuppressive drug used to treat idiopathic membranous nephropathy.

PMID:
12354476
DOI:
10.1016/S0140-6736(02)11042-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center